Clinical trial
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
NCT00429299 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00429299 |
|---|---|
| Title | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer |
| Official title | Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation. |
| Acronym | CHERLOB |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Biological, Drug |
| Interventions | lapatinib, trastuzumab, paclitaxel, fluorouracil, epidoxorubicin, cyclophosphamide |
| Enrollment | 121 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Jan 31, 2007 |
| Last update posted | Mar 22, 2016 |
| Countries | Germany, Italy, Poland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: